| NCT ID | NCT03685331 |
| Title | Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer |
| Recruitment | Not yet recruiting |
| Gender | female |
| Phase | Phase I |
| Variant Requirements | yes |
| Sponsors | Abramson Cancer Center of the University of Pennsylvania |
| Indications | |
| Therapies | |
| Age Groups: | senior adult |